EN DE
Check 40,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Farmacosmo SpA (COSMO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Farmacosmo SpA stock €0.36, price €0.41, that is 13.8% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IT · ISIN IT0005487670

FS Farmacosmo SpA logo Thin data Nov 10, 2026

Farmacosmo SpA

COSMO · MI
Expensive, weak quality

Our calculation puts a fair price 14% below what the stock costs today.

Low debt
Revenue last quarter 34% below a year ago.
Fair value €0.3553 · Overvalued
Quality 38/100
Weak Growth (revenue 3y −5.4 %/yr in EUR)
Loss-making · -5.1% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 12/100
Thin data
Estimate

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€2.59 €0.3810 Fair Value €0.3553 Apr 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

55‑month range €0.3810 – €2.59 · fair‑value band €0.2665 – €0.4442 · the €0.4120 price screens above the €0.3553 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Farmacosmo SpA in your weekly email

Every Wednesday you see whether Farmacosmo SpA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Farmacosmo S.p.A. operates as an e-commerce platform in the wellness sector in Italy.

Show moreShow less

It offers health and pharmacy, vitamins and supplements, bath and body, haircare, sun and tanning, dental care, fragrance, make up, baby and child, toys, organic and natural, food cupboard, pets, and household products. The company was founded in 2013 and is headquartered in Napoli, Italy.

Stock analysis

Farmacosmo SpA (COSMO) currently trades at €0.4120, while our estimate is €0.3553, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.2665 (bear) to €0.4442 (bull), the price of €0.4120 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Farmacosmo SpA reported revenue of €55.7M in FY2025 versus €58.0M in FY2021, a compound −1.0%/yr. Reported net income was −€4.4M in FY2025.

Key figures

Market cap €16.0M Micro · P/S ratio 0.34 · EPS (TTM) €−0.0600 · Net margin −5.1% · Return on equity −42.7% · Return on assets (EBIT) −6.0% (5-year average) · Operating margin −7.0% · Revenue (TTM) €46.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −14%, COSMO screens richer than that median.

Fair Value

Bear €0.2665 Fair Value €0.3553 Bull €0.4442
Price €0.4120 · Downside -13.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 39
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 15
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 17
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 16/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−11.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.9% (2019) → −9.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

COSMO screens overvalued: fair value 14% below the price. Compare with JD Health International Inc →

Compare Farmacosmo SpA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 51 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −13.8% · Below median
Profitability
Return on assets −15.8% · Bottom 25%
Net margin (12 months) −5.1% · Bottom 25%
Operating margin (12 months) −7.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −33.8% · Bottom 25%
Balance sheet
Debt / equity 0.26× · Above median

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/B 2.93× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.35× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 67
FUTURE (revenue growth)0 · sector 20
PAST (return on equity)0 · sector 26
HEALTH (low debt)87 · sector 95
DIVIDEND (yield)0 · sector 57

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
JD Health International Inc 6618 HK$42.84 HK$75.61 +76% vs COSMO
Yifeng Pharmacy Chain Co 603939 ¥24.53 ¥40.59 +65% vs COSMO
Yixintang Pharmaceutical Group 002727 ¥12.81 ¥18.92 +48% vs COSMO
DaShenLin Pharmaceutical Group 603233 ¥20.28 ¥25.52 +26% vs COSMO
LBX Pharmacy Chain Joint Stock Company 603883 ¥14.19 ¥15.61 +10% vs COSMO
Anhui Huaren Health Pharmaceutical Co 301408 ¥14.22 ¥15.40 +8% vs COSMO
DocMorris AG DOCM CHF 18.60 CHF 15.17 −18% vs COSMO
Alibaba Health Information Technology Limited 0241 HK$3.06 HK$2.39 −22% vs COSMO
ShuYu Civilian Pharmacy Corp 301017 ¥14.64 ¥5.91 −60% vs COSMO
Apotea AB APOTEA kr 106.30 kr 39.50 −63% vs COSMO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Farmacosmo SpA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Farmacosmo SpA Fair Value". https://www.fairvalue-calculator.com/stock/COSMO

Frequently asked questions

Is Farmacosmo SpA (COSMO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €0.3553 versus a price of €0.4120, about 14% lower (overvalued).
What is the fair value of COSMO?
Our estimate for Farmacosmo SpA is €0.3553 (as of Nov 10, 2026), built from audited fundamentals. The current price: €0.4120.
What is the quality score of COSMO?
Farmacosmo SpA has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Farmacosmo SpA (COSMO)?
Our calculated price target is the estimate of €0.3553 (as of Nov 10, 2026). Cautious scenario €0.2665, optimistic scenario €0.4442. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Farmacosmo SpA stock forecast for 2026?
Our estimate puts fair value at €0.3553, about 14% lower versus a price of €0.4120 (overvalued). Cautious scenario €0.2665, optimistic scenario €0.4442. The calculation is refreshed regularly with new filings.
What is the revenue of Farmacosmo SpA (COSMO)?
Farmacosmo SpA reported trailing-twelve-month revenue of about €46.2M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Farmacosmo SpA (COSMO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Farmacosmo SpA it is €0.3553 per share (as of Nov 10, 2026), against a price of €0.4120.
Is Farmacosmo SpA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, COSMO trades above its calculated fair value: price €0.4120, fair value €0.3553, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COSMO?
No. The price is what the market pays today (€0.4120); the fair value is what the company's own numbers justify (€0.3553). For Farmacosmo SpA the two are €0.0567 per share apart. That gap is exactly why we show both numbers side by side.
How much is Farmacosmo SpA worth?
The market values Farmacosmo SpA at about €16.0M (market capitalisation, as of Nov 10, 2026). Per share that is €0.4120; our models calculate a fair value of €0.3553 per share.
What do the bullish and bearish scenarios say about COSMO?
Our models span a range for Farmacosmo SpA: cautious scenario €0.2665, base €0.3553, optimistic €0.4442 per share (as of Nov 10, 2026, price €0.4120). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Farmacosmo SpA (COSMO)?
Balance-sheet figures for Farmacosmo SpA (as of Nov 10, 2026): return on equity −42.7%, debt of 0.26 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is COSMO from its 52-week high?
Farmacosmo SpA trades at €0.4120, about 41% below its 52-week high of €0.6960 and 8% above the low of €0.3810 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €0.3553 is for.
Which stocks are comparable to Farmacosmo SpA?
From the same area (Healthcare) we also value JD Health International Inc, Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Farmacosmo SpA stock attractive at the current price?
The data as of Nov 10, 2026: price €0.4120, calculated fair value €0.3553 (−14%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Farmacosmo SpA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Farmacosmo SpA (COSMO)?
The closing price on Nov 10, 2026 was €0.4120. Our estimate is €0.3553, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Farmacosmo SpA right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Farmacosmo SpA

How large is the market capitalisation of Farmacosmo SpA (COSMO)?
The market capitalisation of Farmacosmo SpA is €16.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Farmacosmo SpA (COSMO)?
The price-to-sales ratio of Farmacosmo SpA is 0.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Farmacosmo SpA (COSMO)?
Earnings per share at Farmacosmo SpA are €−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Farmacosmo SpA (COSMO)?
The net margin of Farmacosmo SpA is −5.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Farmacosmo SpA (COSMO)?
The return on equity (ROE) of Farmacosmo SpA is −42.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Farmacosmo SpA (COSMO)?
On an EBIT basis the return on assets of Farmacosmo SpA is −6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Farmacosmo SpA (COSMO)?
The operating margin of Farmacosmo SpA is −7.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Farmacosmo SpA (COSMO)?
Revenue at Farmacosmo SpA is growing −33.8% versus a year earlier (3y avg −5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Farmacosmo SpA (COSMO) generate?
The free cash flow of Farmacosmo SpA is −€2.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.